Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease

Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease Antibody response to pneumococcal vaccination was studied in 76 patients with Hodgkin's disease (HD) before, during and at different time intervals after cessation of therapy. All patients were in pathological stage I and II following explorative laparatomy with splenectomy. The increase in antibody response was compared to the findings in 12 healthy volunteers with the aim of establishing the optimal time for vaccination. Serum antibodies against 6 of the pneumococcal polysaccharide antigens (types 1, 4, 7F, 14, 18C and 23F) contained in the vaccine were determined by an ELISA. Antibody response to pneumococcal type antigens was similar in healthy adults and in patients with early stage HD before therapy. After treatment, post‐vaccination antibody response became negligible. Even up to 7 years after cessation of therapy patients were not able to raise a significant antibody response. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Haematology Wiley

Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease

Download PDF
5 pages

Loading next page...
 
/lp/wiley/antibody-response-to-pneumococcal-vaccine-in-patients-with-early-stage-v09DZ4LYR5

References (21)

Publisher
Wiley
Copyright
© Munksgaard 1989
ISSN
0902-4441
eISSN
1600-0609
DOI
10.1111/j.1600-0609.1989.tb01250.x
Publisher site
See Article on Publisher Site

Abstract

Antibody response to pneumococcal vaccination was studied in 76 patients with Hodgkin's disease (HD) before, during and at different time intervals after cessation of therapy. All patients were in pathological stage I and II following explorative laparatomy with splenectomy. The increase in antibody response was compared to the findings in 12 healthy volunteers with the aim of establishing the optimal time for vaccination. Serum antibodies against 6 of the pneumococcal polysaccharide antigens (types 1, 4, 7F, 14, 18C and 23F) contained in the vaccine were determined by an ELISA. Antibody response to pneumococcal type antigens was similar in healthy adults and in patients with early stage HD before therapy. After treatment, post‐vaccination antibody response became negligible. Even up to 7 years after cessation of therapy patients were not able to raise a significant antibody response.

Journal

European Journal of Haematology – Wiley

Published: Jul 1, 1989

There are no references for this article.